Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors

被引:6
|
作者
Ruiz Castro, Beatriz Guerreiro [1 ]
Souza, Cristiano de Padua [2 ]
Mattos da Cunha Andrade, Carlos Eduardo [3 ]
Vieira, Marcelo de Andrade [3 ]
Pinto de Andrade, Diocesio Alves [4 ]
dos Reis, Ricardo [3 ]
机构
[1] Fac Ciencias Saude Barretos Dr Paulo Prata, Barretos, SP, Brazil
[2] Hosp Canc Barretos, Gynecol Clin Oncol Dept, Barretos, SP, Brazil
[3] Hosp Canc Barretos, Gynecol Oncol Dept, Barretos, SP, Brazil
[4] Inst Oncol Ribeirao Preto, InORP ONCOCLIN Grp, Ribeirao Preto, SP, Brazil
来源
REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA | 2019年 / 41卷 / 07期
关键词
ovarian neoplasms; Sertoli-Leydig cell tumor; oncologic prognosis; CORD-STROMAL TUMORS; CLINICOPATHOLOGICAL ANALYSIS; HYPERESTROGENISM; MANAGEMENT;
D O I
10.1055/s-0039-1693056
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To describe a series of cases of ovarian Sertoli-Leydig cell tumors (SLCTs). Methods Retrospective review of 12 cases of SLCT treated at the Hospital do Cancer de Barretos, Barretos, state of Sao Paulo, Brazil, between October 2009 and August 2017. Results The median age of the patients was 31 years old (15-71 years old). A total of 9 patients (75.0%) presented symptoms: 8 (66.7%) presented with abdominal pain, 5 (41.7%) presented with abdominal enlargement, 2 (16.7%) presented with virilizing signs, 2 (16.7%) presented with abnormal uterine bleeding, 1 (8.3%) presented with dyspareunia, and 1 (8.3%) presented with weight loss. The median preoperative lactate dehydrogenase (LDH) was 504.5 U/L (138-569 UAL), alpha-fetoprotein (AFP) was 2.0 ng/ml (1.1-11.3 ng/ml), human chorionic gonadotropin (beta-hCG) was 0.6 mUl/ml (0.0-2.3 mUl(ml), carcinoem-bryonic antigen (CEA) was 0.9 ng/ml (0.7-3.4 ng/ml), and cancer antigen 125 (CA-125) was 26.0 U/ml (19.1-147.0 U/ml). All of the tumors were unilateral and surgically treated. Lymphadenectomy was performed in 3 (25.0%) patients, but none of the three patients submitted to lymphadenectomy presented lymph node involvement. In the anatomopa-thological exam, 1 (8.3%) tumor was well-differentiated, 8 (66.7%) were moderately differentiated, and 3 (25.0%) were poorly differentiated. A total of 5 (55.6%) tumors were solid-cystic, 2 (22.2%) were purely cystic, 1 (11.1%) was cystic with vegetations, and 1 (11.1%) was purely solid, but for 3 patients this information was not available. The median lesion size was 14.2 cm (3.2-23.5 cm). All of the tumors were at stage IA of the 2014 classification of the International Federation of Gynecology and Obstetrics (FIGO). A total of 2 (16.7%) patients received adjuvant treatment; 1 of them underwent 3 cycles of paclitaxel and carboplatin every 21 days, and the other underwent 4 cycles of ifosfamide, cisplatin and etoposide every 21 days. None of all of the patients had recurrence, and one death related to complications after surgical staging occurred. Conclusion Abdominal pain was the most frequent presentation. There was no ultrasonographic pattern. All of the SLCTs were at stage IA, and most of them were moderately differentiated. Relapses did not occur, but one death related to the surgical staging occurred.
引用
收藏
页码:440 / 448
页数:9
相关论文
共 50 条
  • [21] Characteristics and prognostic implications of a cohort of 50 Sertoli-Leydig cell tumors at a single center
    Kang, Jia
    Mei, Dongyan
    Xing, Xiaoyan
    Cao, Yang
    Liang, Dandan
    Shi, Honghui
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2025, 168 (02) : 613 - 619
  • [22] Estrogen receptor a and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors
    Farinola, Maryam A.
    Gown, Allen M.
    Judson, Kara
    Ronnett, Brigitte M.
    Barry, Todd S.
    Movahedi-Lankarani, Saeid
    Vang, Russell
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2007, 26 (04) : 375 - 382
  • [23] Sertoli-Leydig cell tumor
    Lantzsch, T
    Stoerer, S
    Lawrenz, K
    Buchmann, J
    Strauss, HG
    Koelbl, H
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2001, 264 (04) : 206 - 208
  • [24] Sertoli-Leydig cell tumor
    T. Lantzsch
    S. Stoerer
    K. Lawrenz
    J. Buchmann
    H.-G. Strauss
    H. Koelbl
    Archives of Gynecology and Obstetrics, 2001, 264 : 206 - 208
  • [25] Sertoli-Leydig cell tumor of the ovary: Analysis of a single institution database
    Bhat, Rani Akhil
    Lim, Yong Kuei
    Chia, Yin Nin
    Yam, Kwai Lam
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2013, 39 (01) : 305 - 310
  • [26] Characteristics and outcomes analysis of ovarian Sertoli-Leydig cell tumors (SLCTs): analysis of 15 patients
    Wang, Guangning
    Zhang, Ran
    Li, Chuan
    Chen, Aiping
    JOURNAL OF OVARIAN RESEARCH, 2021, 14 (01)
  • [27] A molecular and immunohistochemical study of 37 cases of ovarian Sertoli-Leydig cell tumor
    Nemejcova, Kristyna
    Hajkova, Nikola
    Krkavcova, Eva
    Bartu, Michaela Kendall
    Michalkova, Romana
    Safanda, Adam
    Svajdler, Marian
    Shatokhina, Tetiana
    Laco, Jan
    Matej, Radoslav
    Hausnerova, Jitka
    Skarda, Jozef
    Nalezinska, Monika
    Zima, Tomas
    Dundr, Pavel
    VIRCHOWS ARCHIV, 2024,
  • [28] Ovarian Sertoli-Leydig and granulosa cell tumor: comparison of epidemiology and survival outcomes
    Nasioudis, Dimitrios
    Mastroyannis, Spyridon A.
    Haggerty, Ashley F.
    Ko, Emily M.
    Latif, Nawar A.
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2020, 302 (02) : 481 - 486
  • [29] DICER1 hotspot mutations in ovarian Sertoli-Leydig cell tumors: a potential association with androgenic effects
    Kato, Noriko
    Kusumi, Tomomi
    Kamataki, Akihisa
    Tsunoda, Rikiya
    Fukase, Masayuki
    Kurose, Akira
    HUMAN PATHOLOGY, 2017, 59 : 41 - 47
  • [30] Ovarian Sertoli-Leydig Cell Tumor With Heterologous Hepatocytes and a Hepatocellular Carcinomatous Element
    Yamamoto, Sohei
    Sakai, Yu
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2019, 38 (03) : 247 - 252